Therapeutic Asset Ratings

138 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Enasidenib Myelodysplastic Syndromes	National Cancer Institute (NCI)	P2	CCC (55)
Hpc, Cord Blood Myelodysplastic Syndromes	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
bgb324 Myelodysplastic Syndromes	BerGenBio ASA	P2	CCC (54)
Treg Cells Myelodysplastic Syndromes	Masonic Cancer Center, University of Minnesota	P2	CCC (54)
Vedolizumab Myelodysplastic Syndromes	City of Hope Medical Center	P3	CCC (53)
Decitabine Myelodysplastic Syndromes	Otsuka Australia Pharmaceutical Pty Ltd	P3	CCC (52)
Dexrazoxane Myelodysplastic Syndromes	Andrew E. Place, MD	P2	CCC (52)
Erwinia L-Asparaginase Myelodysplastic Syndromes	Andrew E. Place, MD	P2	CCC (52)
HUMAN IMMUNOGLOBULINS Myelodysplastic Syndromes	Center for International Blood and Marrow Transplant Research	P2	CCC (52)
Interferon Gamma-1B Myelodysplastic Syndromes	Sawa Ito, MD	P2	CCC (51)
tcb008 Myelodysplastic Syndromes	TC Biopharm	P2	CCC (51)
Rimiducid Myelodysplastic Syndromes	Fred Hutchinson Cancer Center	P2/3	CCC (51)
Baricitinib Myelodysplastic Syndromes	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	CCC (50)
Pembrolizumab Myelodysplastic Syndromes	City of Hope Medical Center	P1	CCC (49)
Ocifisertib Myelodysplastic Syndromes	Treadwell Therapeutics, Inc	P1/2	CCC (49)
Cytokine-Induced Memory-Like Nk Cells Myelodysplastic Syndromes	Washington University School of Medicine	P2	CCC (48)
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) Myelodysplastic Syndromes	GCP-Service International West GmbH	P2	CCC (48)
E-7820 Myelodysplastic Syndromes	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
HUMAN FAECAL MATTER Myelodysplastic Syndromes	University Hospital, Clermont-Ferrand	P2	CCC (48)
RETINOL Myelodysplastic Syndromes	St. Petersburg State Pavlov Medical University	P2	CCC (48)
Tranexamic Acid Myelodysplastic Syndromes	University of Manitoba	P2	CCC (48)
Venclyxto Myelodysplastic Syndromes	First Affiliated Hospital of Zhejiang University	P2	CCC (48)
VITAMIN D Myelodysplastic Syndromes	St. Petersburg State Pavlov Medical University	P2	CCC (48)
Itacitinib Myelodysplastic Syndromes	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CC (47)
APG 115 Myelodysplastic Syndromes	Ascentage Pharma Group Inc.	P1/2	CC (46)

Showing 51 to 75 of 138 assets

PreviousPage 3 of 6Next